ECSP055832A - Dihidrofenantridinosulfonamidas sustituidas - Google Patents
Dihidrofenantridinosulfonamidas sustituidasInfo
- Publication number
- ECSP055832A ECSP055832A EC2005005832A ECSP055832A ECSP055832A EC SP055832 A ECSP055832 A EC SP055832A EC 2005005832 A EC2005005832 A EC 2005005832A EC SP055832 A ECSP055832 A EC SP055832A EC SP055832 A ECSP055832 A EC SP055832A
- Authority
- EC
- Ecuador
- Prior art keywords
- dihydrophenantridinosulphonamids
- substituted
- arthritis
- diseases
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de las fórmulas (I) o (II) que tiene la estructura o una sal farmacéuticamente acceptable de él que son útiles para el tratamiento del componente inflamatorio de enfermedades y son particularmente útiles en el tratamiento de aterosclerosis, infarto de miocardio, insuficiencia cardíaca congestiva, enfermedad intestinal inflamatoria, artritis, diabetes tipo II, y enfermedades autoinmunes como esclerosis múltiple y artritis reumatoide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43094902P | 2002-12-04 | 2002-12-04 | |
US10/718,461 US6894061B2 (en) | 2002-12-04 | 2003-11-20 | Substituted dihydrophenanthridinesulfonamides |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055832A true ECSP055832A (es) | 2005-08-11 |
Family
ID=32474616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005832A ECSP055832A (es) | 2002-12-04 | 2005-06-02 | Dihidrofenantridinosulfonamidas sustituidas |
Country Status (19)
Country | Link |
---|---|
US (1) | US6894061B2 (es) |
EP (1) | EP1567502B1 (es) |
JP (1) | JP4465280B2 (es) |
KR (1) | KR20050085321A (es) |
AT (1) | ATE370934T1 (es) |
AU (1) | AU2003298819A1 (es) |
BR (1) | BR0316196A (es) |
CA (1) | CA2508329A1 (es) |
CR (1) | CR7854A (es) |
DE (1) | DE60315874T2 (es) |
DK (1) | DK1567502T3 (es) |
EC (1) | ECSP055832A (es) |
ES (1) | ES2291739T3 (es) |
MX (1) | MXPA05006003A (es) |
NO (1) | NO20053204L (es) |
NZ (1) | NZ540440A (es) |
RU (1) | RU2005118070A (es) |
TW (1) | TW200510322A (es) |
WO (1) | WO2004050631A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050113405A1 (en) * | 2003-09-24 | 2005-05-26 | Wyeth | Methods of treating rheumatoid arthritis using NF-kB inhibitors |
US20050119276A1 (en) * | 2003-09-24 | 2005-06-02 | Wyeth | Methods of treating inflammatory bowel disease using NF-kB inhibitors |
EP1652841A1 (en) * | 2004-04-30 | 2006-05-03 | Switch Biotech Aktiengesellschaft | Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes |
CN1968932A (zh) | 2004-06-18 | 2007-05-23 | 惠氏公司 | 制备6-烷基-5-芳基磺酰基-二氢菲啶的方法 |
US7304073B2 (en) * | 2004-08-20 | 2007-12-04 | Wyeth | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors |
CA2578933A1 (en) * | 2004-09-02 | 2006-03-16 | Wyeth | Phenanthridine carbonyl phenols as cytokine modulators |
AU2006206534A1 (en) | 2005-01-19 | 2006-07-27 | Wyeth | Estrogen receptor structure |
HU230518B1 (hu) * | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
CN102015606B (zh) | 2007-06-08 | 2015-02-04 | 满康德股份有限公司 | IRE-1α抑制剂 |
US20100080786A1 (en) | 2008-05-20 | 2010-04-01 | Markus Berger | Phenyl or Pyridinyl Substituted Indazoles Derivatives |
EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
CA2947290A1 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションLycera Corporation | RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
WO2020117894A1 (en) * | 2018-12-05 | 2020-06-11 | The Board Of Trustees Of The University Of Illinois | Isocarbostyril alkaloids and functionalization thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1135947A (en) | 1965-04-20 | 1968-12-11 | Aspro Nicholas Ltd | Novel biologically active derivatives of phenanthridone |
EP0509780A1 (en) | 1991-04-16 | 1992-10-21 | Merck & Co. Inc. | 2-phenanthridonyl carbapenems |
EP0509756A1 (en) | 1991-04-16 | 1992-10-21 | Merck & Co. Inc. | 2-Phenanthridonyl carbapenems having cationizeable substituents |
US5153185A (en) | 1991-04-16 | 1992-10-06 | Merck & Co., Inc. | 2-phenanthridonyl carbapenems |
US5726186A (en) | 1995-09-08 | 1998-03-10 | Eli Lilly And Company | Pentacyclic compounds, intermediates, processes, compositions, and methods |
HUP0003311A3 (en) | 1997-07-25 | 2002-10-28 | Altana Pharma Ag | Substituted 6-phenylphenanthridine derivatives, pocess for producing them and pharmaceutical compositions containing them |
WO2000042018A1 (en) | 1999-01-15 | 2000-07-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
CA2359440C (en) | 1999-01-15 | 2009-04-14 | Beate Gutterer | Phenylphenanthridines with pde-iv inhibiting activity |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
WO2002005616A1 (en) | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
WO2002020463A2 (en) | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
-
2003
- 2003-11-20 US US10/718,461 patent/US6894061B2/en not_active Expired - Fee Related
- 2003-12-02 NZ NZ540440A patent/NZ540440A/en unknown
- 2003-12-02 EP EP03796577A patent/EP1567502B1/en not_active Expired - Lifetime
- 2003-12-02 RU RU2005118070/04A patent/RU2005118070A/ru not_active Application Discontinuation
- 2003-12-02 CA CA002508329A patent/CA2508329A1/en not_active Abandoned
- 2003-12-02 JP JP2004557494A patent/JP4465280B2/ja not_active Expired - Fee Related
- 2003-12-02 MX MXPA05006003A patent/MXPA05006003A/es active IP Right Grant
- 2003-12-02 WO PCT/US2003/038290 patent/WO2004050631A1/en active IP Right Grant
- 2003-12-02 ES ES03796577T patent/ES2291739T3/es not_active Expired - Lifetime
- 2003-12-02 BR BR0316196-0A patent/BR0316196A/pt not_active IP Right Cessation
- 2003-12-02 KR KR1020057010047A patent/KR20050085321A/ko not_active Application Discontinuation
- 2003-12-02 AT AT03796577T patent/ATE370934T1/de not_active IP Right Cessation
- 2003-12-02 DE DE60315874T patent/DE60315874T2/de not_active Expired - Lifetime
- 2003-12-02 AU AU2003298819A patent/AU2003298819A1/en not_active Withdrawn
- 2003-12-02 DK DK03796577T patent/DK1567502T3/da active
- 2003-12-04 TW TW092134185A patent/TW200510322A/zh unknown
-
2005
- 2005-06-02 EC EC2005005832A patent/ECSP055832A/es unknown
- 2005-06-02 CR CR7854A patent/CR7854A/es not_active Application Discontinuation
- 2005-06-30 NO NO20053204A patent/NO20053204L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2508329A1 (en) | 2004-06-17 |
NO20053204L (no) | 2005-09-05 |
BR0316196A (pt) | 2005-09-27 |
DE60315874D1 (de) | 2007-10-04 |
DK1567502T3 (da) | 2007-10-29 |
CR7854A (es) | 2006-04-28 |
NZ540440A (en) | 2006-11-30 |
JP4465280B2 (ja) | 2010-05-19 |
RU2005118070A (ru) | 2006-01-27 |
DE60315874T2 (de) | 2008-05-15 |
NO20053204D0 (no) | 2005-06-30 |
MXPA05006003A (es) | 2005-08-18 |
JP2006510631A (ja) | 2006-03-30 |
US20040167155A1 (en) | 2004-08-26 |
KR20050085321A (ko) | 2005-08-29 |
EP1567502A1 (en) | 2005-08-31 |
ES2291739T3 (es) | 2008-03-01 |
WO2004050631A1 (en) | 2004-06-17 |
ATE370934T1 (de) | 2007-09-15 |
AU2003298819A1 (en) | 2004-06-23 |
TW200510322A (en) | 2005-03-16 |
US6894061B2 (en) | 2005-05-17 |
EP1567502B1 (en) | 2007-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055832A (es) | Dihidrofenantridinosulfonamidas sustituidas | |
MXPA05011581A (es) | Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos. | |
ATE473980T1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
NO20062950L (no) | 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet | |
NO20083743L (no) | Pyrimidinylsulfonamidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4 | |
BR0311343A (pt) | Derivados de piridazina | |
EA201070423A1 (ru) | Диарильные соединения оксадиазолов | |
PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
TR200201187T2 (tr) | Ters transkriptazın inhibitörleri olarak benzofenonlar | |
DK1940826T3 (da) | Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4 | |
BR9811599A (pt) | Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4 | |
EA201070238A1 (ru) | Соединения пиримидина | |
DE60226154D1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
NO20043900L (no) | Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner | |
DE60002714D1 (de) | Substituierte azaoxindolederivate | |
MX2010007026A (es) | Derivados de triazoloxadiazoles. | |
EA200500803A1 (ru) | Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний | |
MXPA05007607A (es) | Inhibidores amida y ester de la metaloproteinasa de matriz. | |
EA200400438A1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии | |
ATE346040T1 (de) | Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit | |
BRPI0415355A (pt) | triarilimidazóis | |
PT1334094E (pt) | Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol | |
NO20053562L (no) | Nye aminobenzofenonforbindelser | |
HK1085467A1 (en) | Substituted heterocyclic compounds | |
DE50200864D1 (de) | Verbundelemente enthaltend bitumen |